We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Desktop Analyzer Performs Chemical, Turbidimetric Tests, and Immunoassays

By LabMedica International staff writers
Posted on 10 Nov 2010
A desktop analyzer uses innovative technology to allow simultaneous measurement of immunoassays and clinical chemistry parameters, including turbidimetric tests in one sample.

The fully automated, random access analyzer is ideal for medium-sized and small laboratories, and it will provide diagnostic services to hospitals, clinics, and large medical practice facilities.

Image: The DRG Hybrid-XL (photo courtesy DRG International).
Image: The DRG Hybrid-XL (photo courtesy DRG International).

The analyzer, which is called DRG:Hybrid-XL, is also ideal for high work-load labs performing routine and niche diagnostic parameters on large automatic equipment. Up to 40 tests of different types or 40 times the same test, or up to 20-patient samples can be ordered by the medical practitioner over a wide range of prepackaged tests to serve different specialties, such as gynecology, oncology, prenatal supervision, cardiac markers, infectious diseases, and other common diseases.

DRG (Mountainside, NJ, USA) plans to showcase the new analyzer DRG:Hybrid-XL at MEDICA 2010, which will take place for four days from November 17, 2010 in Düsseldorf, Germany. It will be available for use in summer 2011.

Cyril E. Geacintov Ph.D., founder, CEO, and president of DRG, said, "The DRG:Hybrid-XL will allow laboratories to conduct specific testing on-site,” he says. "This will provide for faster and more accurate test results with greater convenience.”

Related Links:

DRG International Inc.






Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS

Latest Immunology News

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
10 Nov 2010  |   Immunology

Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
10 Nov 2010  |   Immunology

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
10 Nov 2010  |   Immunology